News

November's Personal Consumption Expenditures report is the latest data point that will shape future monetary policy.

Bitcoin sunk below $92,000 early Friday before recovering some ground, on the heels of the Federal Reserve signaling a slowdown in interest rate cuts for 2025.

(Bloomberg) -- Federal Reserve Bank of San Francisco President Mary Daly said she is “very comfortable” with policymakers’ median projection of two interest-rate cuts next year, emphasizing the central bank can turn to a slower approach.Most Read from BloombergNew York City’s Historic Preservation Movement Is Having a Midlife CrisisNYPD Car Chases Are Becoming More Frequent — and More DangerousDakar’s Air Quality Plummets as Saharan Dust Descends on SenegalReviving a Little-Known Modernist Landm

LONDON (Reuters) -Oil prices fell on Friday on worries about demand growth in 2025, especially in top crude importer China, putting global oil benchmarks on track to end the week down more than 3%. Chinese state-owned refiner Sinopec said in its annual energy outlook released on Thursday that China's crude imports could peak as soon as 2025 and the country's oil consumption would peak by 2027 as diesel and gasoline demand weaken. "Benchmark crude prices are in a prolonged consolidation phase as the market heads towards the year-end weighed by uncertainty in oil demand growth," said Emril Jamil, senior research specialist at LSEG.

Winnebago Industries, Inc. (NYSE:WGO) shares are trading lower in the premarket session on Friday. The company reported first-quarter adjusted loss per share of 3 cents, missing the analyst consensus estimate for EPS of 20 cents. Quarterly sales were $625.60 million (down 18%), which was missing the analyst consensus estimate of $672.232 million. Revenues fell amid lower unit volume and a reduced average selling price per unit related to product mix. Gross profit was $76.8 million, a decrease of

On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and when autologous vein graft is not feasible. Symvess, or the ATEV, is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for arterial replacement and repair. Also Read: Delay Hits Humac

Bitcoin Plunges to $93K, Dogecoin Down 27% as Crypto Bloodbath Goes On